Immix Biopharma in-licenses NXC-201, Demonstrating High CRR in Heavily Pre-Treated Multiple Myeloma (71% CR) Patients December 19, 2022
Clovis Oncology Files For Chapter 11 Protection And Enters Bankruptcy With Agreement To Sell FAP-2286 to Novartis December 19, 2022
Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs December 19, 2022
Adagene and Roche to Evaluate SAFEbody® ADG126 in Combination with Standard-of-Care for 1L HCC December 19, 2022
Safety Review Committee Approves to Proceed to Final Cohort in Acclaim-1 Ph 1 Dose Escalation Trial of REQORSA® + Tagrisso® in Advanced NSCLC December 19, 2022
mRNA-4157/V940 + KEYTRUDA® (pembrolizumab) Met Primary Efficacy Endpoint in Ph 2b KEYNOTE-942 Trial December 19, 2022
Zolbetuximab Meets Primary Endpoint in Ph 3 GLOW Trial as 1L Treatment in Claudin 18.2 +ve HER2-neg Locally Advanced Unresectable or Metastatic GEJ Cancers December 19, 2022
Initial Data from the Ongoing Ph 2B VITALIZE Trial in Patients with r/r DLBCL announced December 19, 2022
80% ORR reported in Final Cohort of Ph 1 Single Agent Trial of Annamycin for the Treatment of AML December 19, 2022
Double-Digit ORR announced in Each Cohort from the Ongoing ENVASARC Ph 2 Pivotal Trial December 19, 2022
Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) + Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma December 19, 2022
PDUFA date extended by three months to review Lynparza + abiraterone & prednisone supplemental NDA for metastatic CRPC December 19, 2022
Application in European Union Seeking Approval of IMBRUVICA (ibrutinib) for the Treatment of Patients with Untreated Mantle Cell Lymphoma withdrawn December 19, 2022
U.S. FDA announces Accelerated Approval of KRAZATI™ (adagrasib) for Patients with Locally Advanced or Metastatic NSCLC with a KRASG12C Mutation December 19, 2022
European Commission Approves Pluvicto® For Treatment Of Progressive PSMA+ve metastatic CRPC December 19, 2022
